Another, non-redundant (PRR independent) strategy to activate myeloid cells to directly reshape TME contexture and sustain a tumour-specific T cell immune response is mediated by CD40 triggering, which is able to support immune response in tumours resistant to immunotherapy such as PDAC, in both mouse models and human patients [210, 211]. This evidence concerns the gene CD40 and neoplasm.